AJANTPHARM — Ajanta Pharma Income Statement
0.000.00%
- IN₹334.26bn
- IN₹327.02bn
- IN₹42.09bn
- 99
- 13
- 70
- 68
Annual income statement for Ajanta Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 25,879 | 28,897 | 33,410 | 37,426 | 42,087 |
Cost of Revenue | |||||
Gross Profit | 18,976 | 22,073 | 24,543 | 26,259 | 30,934 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20,041 | 20,050 | 25,331 | 30,620 | 31,561 |
Operating Profit | 5,838 | 8,847 | 8,079 | 6,806 | 10,526 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,640 | 9,002 | 9,095 | 7,453 | 11,139 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,677 | 6,539 | 7,127 | 5,880 | 8,162 |
Net Income Before Extraordinary Items | |||||
Net Income | 4,677 | 6,539 | 7,127 | 5,880 | 8,162 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4,677 | 6,539 | 7,127 | 5,880 | 8,162 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 36.4 | 50.6 | 55.4 | 46.3 | 65 |
Dividends per Share | |||||
Special Dividends per Share |